CA
NZ
UK
AU
IND
US
…
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Anika Therapeutics develops and markets hyaluronic acid–based therapeutics and regenerative medical devices for orthopedics and soft-tissue repair, including intra‑articular injections for osteoarthritis. Long-term growth may be supported by aging populations, rising osteoarthritis prevalence and international expansion, and investors may find the company attractive for its niche product portfolio, manufacturing capabilities and recurring procedure-driven demand.
Key risks include reimbursement and regulatory pressure, competition from alternative therapies and concentration from reliance on a small number of orthopedic products and manufacturing capacity.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -18.75M | 2.43M | -28.62M | 36.12M | 23.21M |
| Net income | -14.86M | 4.13M | -23.98M | 27.19M | 18.72M |
| Selling general administrative | 84.79M | 53.00M | 60.06M | 34.95M | 34.34M |
| Gross profit | 93.58M | 82.94M | 69.03M | 85.86M | 74.28M |
| Reconciled depreciation | 14.49M | 14.32M | 13.46M | 5.99M | 5.91M |
| Ebit | -33.89M | -18.48M | -14.47M | 28.26M | 15.84M |
| Ebitda | -19.40M | -39.58M | -0.61M | 34.25M | 21.75M |
| Depreciation and amortization | 14.49M | -21.09M | 13.85M | 5.99M | 5.91M |
| Operating income | -19.40M | -18.48M | -14.47M | 34.25M | 21.75M |
| Other operating expenses | 175.64M | 166.27M | 144.93M | 80.36M | 83.81M |
| Interest expense | 0.65M | -0.19M | -0.30M | 7.86M | 1.46M |
| Tax provision | -3.89M | -1.71M | -4.64M | 8.93M | 4.49M |
| Interest income | - | - | - | 1.87M | 1.46M |
| Net interest income | 0.65M | -0.19M | -0.30M | 1.87M | 1.46M |
| Non recurring | - | - | 42.52M | - | - |
| Income tax expense | -3.89M | -1.71M | -4.64M | 8.93M | 4.49M |
| Total revenue | 156.24M | 147.79M | 130.46M | 114.61M | 105.56M |
| Total operating expenses | 112.98M | 101.42M | 83.49M | 51.62M | 52.53M |
| Cost of revenue | 62.66M | 64.85M | 61.43M | 28.75M | 31.28M |
| Total other income expense net | 0.65M | 20.91M | -14.16M | 1.87M | 1.46M |
| Net income from continuing ops | -14.86M | 4.13M | -23.98M | 27.19M | 18.72M |
| Net income applicable to common shares | -14.86M | 4.13M | -23.98M | 27.19M | 18.72M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 270.63M | 349.13M | 347.54M | 365.61M | 330.71M |
| Intangible assets | 4.63M | 74.60M | 82.38M | 91.16M | 7.58M |
| Other current assets | 8.10M | 8.83M | 8.29M | 8.75M | 1.44M |
| Total liab | 58.37M | 63.56M | 60.45M | 93.20M | 42.33M |
| Total stockholder equity | 212.26M | 285.56M | 287.08M | 272.40M | 288.38M |
| Deferred long term liab | - | 6.44M | 10.16M | 11.89M | 4.33M |
| Other current liab | 17.83M | 16.77M | 4.32M | 13.09M | 11.30M |
| Common stock | 0.15M | 0.15M | 0.14M | 0.14M | 0.14M |
| Capital stock | 0.15M | 0.15M | 0.14M | 0.14M | 0.14M |
| Retained earnings | 128.05M | 210.72M | 225.58M | 221.44M | 245.43M |
| Other liab | - | 6.83M | 11.41M | 35.46M | 4.69M |
| Good will | 7.57M | 7.34M | 7.78M | 8.41M | 7.69M |
| Other assets | - | 18.67M | 20.29M | 38.04M | -1.44M |
| Cash | 72.87M | 86.33M | 94.39M | 95.82M | 157.46M |
| Total current liabilities | 31.06M | 27.91M | 29.80M | 36.87M | 16.28M |
| Current deferred revenue | 1.24M | - | 16.13M | 13.21M | - |
| Net debt | -43.83M | -55.44M | -75.15M | -74.94M | -136.10M |
| Short term debt | 2.13M | 2.07M | 1.71M | 1.58M | 1.14M |
| Short long term debt total | 29.04M | 30.89M | 19.24M | 20.88M | 21.37M |
| Other stockholder equity | 90.01M | 81.14M | 67.08M | 55.35M | 48.71M |
| Property plant equipment | - | 48.28M | 47.60M | 50.61M | 50.78M |
| Total current assets | 163.31M | 169.55M | 168.53M | 177.38M | 235.75M |
| Net tangible assets | - | 232.44M | 216.16M | 193.71M | 294.47M |
| Short term investments | - | 34.63M | - | 2.50M | 27.48M |
| Net receivables | 35.96M | 34.63M | 29.84M | 24.10M | 23.08M |
| Inventory | 46.39M | 39.77M | 36.01M | 46.21M | 22.00M |
| Accounts payable | 9.86M | 9.07M | 7.63M | 8.98M | 3.83M |
| Accumulated other comprehensive income | -5.94M | -6.44M | -5.72M | -4.54M | -5.90M |
| Common stock total equity | - | 0.15M | 0.14M | 0.14M | 0.14M |
| Retained earnings total equity | - | 210.72M | 225.58M | 221.44M | 245.43M |
| Non currrent assets other | 14.05M | 17.22M | 20.29M | 15.42M | 7.48M |
| Non current assets total | 107.32M | 179.58M | 179.01M | 188.22M | 96.40M |
| Capital lease obligations | 29.04M | 28.82M | 20.95M | 20.88M | 22.51M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -7.49M | 2.50M | 24.96M | 42.52M | -45.60M |
| Change to liabilities | 2.96M | 1.10M | -1.39M | 3.49M | 0.56M |
| Total cashflows from investing activities | -7.49M | -3.12M | -71.26M | 39.69M | -50.26M |
| Net borrowings | -0.28M | -0.20M | -0.35M | -0.56M | -0.56M |
| Total cash from financing activities | -4.85M | -6.78M | -3.77M | -8.14M | -28.90M |
| Change to operating activities | -2.72M | 0.53M | -3.89M | 1.10M | 2.21M |
| Net income | -14.86M | 4.13M | -23.98M | 27.19M | 18.72M |
| Change in cash | -8.06M | -1.43M | -61.65M | 68.42M | -44.21M |
| Begin period cash flow | 94.39M | 95.82M | 157.46M | 89.04M | 133.26M |
| End period cash flow | 86.33M | 94.39M | 95.82M | 157.46M | 89.04M |
| Total cash from operating activities | 4.41M | 8.40M | 13.06M | 37.01M | 34.92M |
| Depreciation | 14.49M | 14.32M | 13.46M | 5.99M | 5.91M |
| Other cashflows from investing activities | - | -0.48M | -94.60M | 42.52M | -45.60M |
| Change to inventory | -6.87M | -6.62M | -14.18M | -5.58M | -7.58M |
| Change to account receivables | -5.63M | -6.22M | 5.86M | -1.84M | 2.91M |
| Sale purchase of stock | 0.68M | 1.13M | 1.52M | -30.00M | -30.00M |
| Other cashflows from financing activities | -4.57M | -6.58M | 46.78M | 21.86M | 1.10M |
| Change to netincome | 14.75M | -3.51M | 24.45M | 9.29M | 13.49M |
| Capital expenditures | 7.49M | 5.14M | 1.63M | 2.83M | 4.66M |
| Change receivables | -5.63M | -6.22M | 5.86M | -1.84M | 2.91M |
| Cash flows other operating | 7.36M | 13.03M | 8.87M | -1.53M | 0.90M |
| Exchange rate changes | - | - | - | -0.13M | 0.03M |
| Cash and cash equivalents changes | -7.93M | -1.50M | -61.97M | 68.42M | -44.21M |
| Change in working capital | -11.82M | -14.72M | -13.46M | -6.64M | -3.20M |
| Stock based compensation | 14.31M | 11.09M | 5.39M | 6.09M | 11.05M |
| Other non cash items | 7.56M | -4.66M | 35.20M | 3.58M | 4.26M |
| Free cash flow | -3.08M | 3.25M | 11.44M | 34.18M | 30.26M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ANIK Anika Therapeutics Inc |
0.08 0.38% |
21.35 | - | 36.63 | 1.59 | 1.40 | 1.32 | -72.65 |
| MKKGY Merck KGaA ADR |
0.17 0.53% |
32.25 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
161.82 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.16 0.78% |
20.27 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
41.22 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. Cheryl Renee Blanchard Ph.D. | Pres, CEO & Director | 1964 |
| Mr. Michael L. Levitz | Exec. VP, CFO & Treasurer | 1974 |
| Mr. David Colleran | Exec. VP, Gen. Counsel & Corp. Sec. | 1972 |
| Ms. Anne Nunes | VP of Operations | NA |
| Mr. Mark Namaroff | Exec. Director of Investor Relations & Corp. Communications | 1963 |
| Mr. Charles Sherwood III | VP & Corp. Legal Counsel | NA |
| Mr. James Chase | Sr. VP of International Sales & Marketing | NA |
| Mr. Bart Bracy | VP of Sales & Marketing of Americas | NA |
| Mr. Ben Joseph | VP of Commercial & Corp. Devel. | NA |
| Ms. Lisa Funiciello | VP of HR | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.59%
Communication Services
+0.05%
Consumer Cyclical
+0.14%
Consumer Defensive
-0.43%
Energy
-0.03%
Financial Services
+0.19%
Financials
-0.35%
Healthcare
+1.05%
Industrials
+0.67%
Real Estate
-0.25%
Technology
+1.31%
Utilities
+0.32%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...